Clinical trials
catalyst calendar across sponsors →Studies where MNPR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 2 expanded access
Held by 7 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, GABELLI FUNDS LLC, +2 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequencyNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | Dec 2026 | ≤ 134 d | 2025-05-21 |
| Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsNCT06337084To assess dosimetry and biodistribution of MNPR-101-DFO*-89ZrOpen-label · Diagnostic | Phase 1 | Recruiting | Drug: MNPR-101-DFO*-89Zr · Diagnostic test: PET/CT Diagnostic Imaging | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | Apr 2026 | — | 2025-05-22 |
| Camsirubicin + Pegfilgrastim to Determine MTD in ASTSNCT05043649To determine Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: lack of timely enrollment | Drug: Camsirubicin | Advanced Soft-tissue Sarcoma | 14 | 2023-10-31actual | — | 2024-05-16 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.NCT04648020To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.Randomized · Quadruple-masked · Supportive care | Phase 2/3 | Terminatedsponsor's stated reason: Interim Analysis did not meet the pre-defined threshold for efficacy of a 15% absolute difference in SOM prevention between Validive and placebo. | Drug: Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet | Chemoradiotherapy-Induced Severe Oral Mucositis | 190 | 2023-05-14actual | — | 2023-05-31 |
| MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor CancerNCT06980506expanded access | — | Available | Diagnostic test: MNPR-101-DFO*-89Zr | Cancer, Solid Tumor, Solid Tumor, Adult | — | — | — | 2025-05-22 |
| MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor CancerNCT06980519expanded access | — | Available | Biological: MNPR-101-PCTA-177Lu | Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor | — | — | — | 2025-05-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19